ClinicalTrials.gg
CompletedNCT04413617Updated Apr 7, 2023Results posted

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

A Phase 2 interventional study of PF-06650833 and PF-06651600 in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 144 sites in 10 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-04-07.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 152 studies in Arthritis, Rheumatoid by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.

Enrollment
19th of 86
460 · median 155
Started
2020
with 4 others
Phase 2
28 of 152
none open now
Registered
140th of 152
by date

Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 19th largest by enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2020, is one of 28 in phase 2, and was the 140th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 152 studies in Arthritis, Rheumatoid by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Arthritis, Rheumatoid by Pfizer, or all of them as a file.
02

Study summary

Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants between the ages of 18 and 70 years.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Diagnosis of RA and meeting the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA with a Total Score ≥6/10.
  • The participant has active disease at both Screening and Randomization, as defined by both: ≥6 joints tender or painful on motion, AND ≥6 joints swollen; and fulfills 1 of the following 2 criteria: High sensitivity C reactive protein (hsCRP) >7 mg/L at Screening (Visit 1) as performed by the central laboratory OR Erythrocyte sedimentation rate (ESR) (Westergren method) >28 mm h.

Exclusion criteria

Exclusion Criteria:

  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Participants with a known immunodeficiency disorder or a first degree relative with a hereditary immunodeficiency.
  • Participants with any active or latent infections.
  • Participants with positive surface antigen (HBsAg).
  • Participants with positive Ab tests will be reflex tested for HCV ribonucleic acid (HCV RNA).
  • Any history of either untreated or inadequately treated latent or active tuberculosis (TB) infection, current treatment for active or latent TB infection or evidence of currently active TB,
  • History of a major organ transplant (eg, heart, lung, kidney and liver) or hematopoietic stem cell/marrow transplant.
  • History of severe allergic or anaphylactoid reaction to kinase inhibitors, or preparations.
  • Known history of diverticulitis or symptomatic diverticulosis, perineal abscess or fistulae.
  • Participants with or history of malignancy (including lymphoma, leukemia, or lymphoproliferative disease).
  • Pre-existing chronic disease (eg, inflammatory bowel disease, systemic lupus erythematosus, moderate-severe atopic dermatitis, dermatomyositis) other than RA. Secondary Sjogren's Syndrome (due to RA) may be included.
  • Participants with fibromyalgia will be excluded.
  • Previous treatment with total lymphoid irradiation.
  • Participants with an oral, tympanic, or temporal temperature of 38°C (100.4°F) or higher at baseline.
  • Participants may not receive any live/attenuated vaccine from 30 days prior to randomization during the course of the study, or for 30 days after the last dose of study medication. Participants who have current routine household contact with children who have received varicella or oral polio vaccine within 2 months of first study dose are also excluded.
  • History of any lymphoproliferative disorder.
  • Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease.
  • History of any prior deep vein thrombosis (DVT) or pulmonary embolism [PE].
  • Recent (within 6 months of screening) myocardial infarction, coronary revascularization, or percutaneous angioplasty with or without placement of a coronary artery stent; acute coronary syndrome; chronic uncompensated heart failure or Functional Class III or IV; left ventricular assist devices; implanted defibrillators.
  • Current severe chronic renal insufficiency or renal failure as defined by persistent (on repeated measurements) \<60 mL/min per 1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation.
  • Any known coagulopathy or hypercoagulant syndrome.
  • Presence of any of the following laboratory abnormalities at screening or within the 3 months prior to first study dose:

(ALT) or aspartate aminotransferase (AST) levels ≥1.5 x the (ULN); Participants with a history of Gilbert's syndrome may have a direct measured and would be eligible for this study provided the direct bilirubin is ≤ ULN and other liver function assessments are normal; of \<1.5 x 109/L (\<1500/mm3). Participants with cyclic (benign ethnic) neutropenia will be excluded; Absolute lymphocyte count of \<0.5 x 109/L (\<500/mm3); Absolute white blood cell (WBC) count of \<3.0 x 109/L (\<3000/mm3); \<9.0 g/dL (90 g/L); count ≤100 x 109/L (100,000 cells/mm3) or ≥1000 x 109/L (1,000,000 cells/mm3); Thrombocytopenia, as defined by a platelet count \<100 x 109/L (\<100,000/mm3) at screening visit or within the 3 months prior to first study dose. [Screening laboratory tests with abnormal results may be repeated once to confirm abnormal results. If results return to normal protocol acceptable limits within the 4-week screening period, the participant may enter the study].

  • Grade 3 or greater laboratory abnormality based on the (CTCAE) version 5.0 toxicity scale, except for the following that are allowed: Grade 3 (PT) secondary to warfarin treatment; Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy.
  • Participants previously treated with a biologic DMARD (except for up to 25% of participants who may have been treated with 1, and only 1 prior TNF inhibitor) or any other recent DMARD treatment (eg, a JAK inhibitor), or participants currently treated with any other prohibited medications will be excluded.
  • Prior use of tofacitinib or other JAK inhibitor in the context of a clinical trial is excluded. Concomitant use of tofacitinib (other than as prescribed by the randomization scheme) or other JAK inhibitor is prohibited.
  • Participants who have previously been treated with other, non-TNFa inhibiting biologic DMARDs [including, abatacept (Orencia®), tocilizumab (Actemra®), Sarilumab (Kevzara®), anakinra (Kineret®), rituximab (Rituxan®) or other selective B lymphocyte depleting agents, or other lymphocyte depleting agents/therapies (such as alemtuzab [CamPath®], natalizumab (Tysabri®), alkylating agents [eg, cyclophosphamide or chlorambucil], total lymphoid irradiation) are excluded from participation in the study.
  • Previous administration with an drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of IP used in this study (whichever is longer).
  • Any 12-lead (ECG) performed prior to randomization that demonstrates abnormalities that may affect participant safety or interpretation of study results.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
460 participants (actual)

Study arms

  • Experimental
    PF-06650833 + tofacitinib

    Drug: PF-06650833 · Drug: Tofacitinib

  • Experimental
    PF-06650833 + PF-06651600

    Drug: PF-06650833 · Drug: PF-06651600

  • Experimental
    PF-06650833

    Drug: PF-06650833

  • Experimental
    PF-06651600

    Drug: PF-06651600

  • Experimental
    Tofacitinib

    Drug: Tofacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12

    DAS28 is a measure based on assessment of 28 joints for tenderness and swelling (tender and swollen joint counts). Disease Activity Score 28-C reactive protein (DAS28-CRP) is derived using differential weighting given to 4 components: tender joint count (range: 0-28), swollen joint count (range: 0-28), patient global assessment (recorded on a visual analog scale \[VAS\] scale of 0-100 mm), and CRP (milligram per liter). DAS28-CRP score ranges from 0 to 9.4. The lower the DAS28-CRP score is, the better the participant has response (remission = score\<2.6, low disease activity = score≤3.2). A negative value in change from BL indicates an improvement. Mixed Model Repeated Measures was used for statistical analysis, which used the change from BL of DAS28-CRP as an outcome and treatment, scheduled study visit, BL value of DAS28-CRP, treatment by visit interaction and BL by visit interaction as fixed effects. The model used the unstructured covariance matrix.

    Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12

Secondary outcomes

  1. DAS28-CRP Remission (<2.6) Rates at Week 24

    DAS28-CRP is derived using differential weighting given to 4 components: tender joint count, swollen joint count, patient global assessment, and CRP. Remission is defined as DAS28-CRP score \<2.6. Remission rate = the number of responders (who had remission) / (number of responders + non-responders + non-responder assigned by non-responder imputation \[NRI\] after removal of missingness due to COVID-19 and missing components at a given visit)

    Time frame: Week 24

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs

    An adverse event (AE) was any untoward medical occurrence in a patient or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; or other serious situations such as important medical events. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.

    Time frame: From first dose of study intervention (Day 1) to Week 28

  3. Number of Participants With Clinical Laboratory Abnormalities (Hematology and Chemistry, Without Regard to Baseline Abnormality)

    Clinical laboratory abnormality was determined at the investigator's discretion.

    Time frame: From BL to Week 28

  4. Number of Participants With Change From Baseline in Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria

    Abnormality in change from BL in vital signs included: sitting/semi-supine diastolic blood pressure (BP) increase and decrease from BL of \>=20mmHg, systolic BP increase and decrease from BL of \>=30mmHg

    Time frame: From BL to Week 28

  5. Number of Participants With Adverse Events of Special Interest

    These AEs included severe and opportunistic infection AEs; herpes virus infection AEs; clinically significant categorical increases in hepatic enzymes AST, and ALT and total bilirubin, and potential cases meeting Hy's Law criteria for increased risk of drug induced liver injury (DILI); major adverse cardiovascular events, including pulmonary embolism and deep vein thrombosis, cerebrovascular accident; AEs for decreased renal function, acute kidney injury, clinically significant increases in serum creatinine (Scr) and decreases in estimated glomerular filtration rate (eGFR). Only participants with AEs mentioned above were reported in the table below.

    Time frame: From first dose of study intervention (Day 1) to Week 28

  6. Change From Baseline in DAS28-CRP at Week 24

    DAS28 is a measure based on assessment of 28 joints for tenderness and swelling (tender and swollen joint counts). DAS28-CRP is derived using differential weighting given to 4 components: tender joint count (range: 0-28), swollen joint count (range: 0-28), patient global assessment (recorded on a visual analog scale \[VAS\] scale of 0-100 mm), and CRP (milligram per liter). DAS28-CRP score ranges from 0 to 9.4. The lower the DAS28-CRP score is, the better the participant has response (remission = score\<2.6, low disease activity = score≤3.2). A negative value in change from BL indicates an improvement.

    Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 24

  7. American College of Rheumatology (ACR)20, ACR 50, ACR 70, and ACR 90 Responder Rates at Week 12 and Week 24

    The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR20) is calculated as a \>=20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and CRP. Similarly, ACR50, ACR70, and ACR 90 were calculated with the respective percent improvement. Responder rate = number of responders (who had ACR20/50/70/90 response)/(number of responders + non-responders + non-responder assigned by non-responder imputation \[NRI\] after removal of missingness due to COVID-19 and missing components at a given visit)

    Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12, Week 24

  8. Change From Baseline in the Tender/Painful and Swollen Joint Count at Week 12 and Week 24

    The endpoint included Tender/Painful Joint Count 68 (TJC68) and 28 (TJC28). TJC68 was assessed by a blinded joint assessor to determine the number of joints that were considered tender or painful in upper body and upper/lower extremity. The response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). The 28-joints set is the subset of 68 joints set including the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. TJC28 was calculated by Pfizer from TJC68. Higher scores indicate higher level of disability.

    Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12, Week 24

  9. Change From Baseline in the Physician's Global Assessment (PhGA) of Arthritis at Week 12 and Week 24

    PhGA of Arthritis is an evaluation done by investigator based on the participant's disease signs, functional capacity and physical examination, and should be independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS. Physician's Global Assessment score ranges from 0 to 100. Higher scores indicate higher level of disability. A negative value in change from BL indicates an improvement.

    Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12, Week 24

07

Results

Posted Apr 7, 2023

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mg
Started1027777103101
Completed9571739596
Not completed76485
Withdrew: Refused to come for fu visit and was contacted by phone00010
Withdrew: Protocol violation01001
Withdrew: Lack of efficacy20210
Withdrew: Withdrawal by subject34253
Withdrew: Death10000
Withdrew: Adverse event10011
Withdrew: Covid-1901000

Outcome measures

PrimaryChange From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12

DAS28 is a measure based on assessment of 28 joints for tenderness and swelling (tender and swollen joint counts). Disease Activity Score 28-C reactive protein (DAS28-CRP) is derived using differential weighting given to 4 components: tender joint count (range: 0-28), swollen joint count (range: 0-28), patient global assessment (recorded on a visual analog scale \[VAS\] scale of 0-100 mm), and CRP (milligram per liter). DAS28-CRP score ranges from 0 to 9.4. The lower the DAS28-CRP score is, the better the participant has response (remission = score\<2.6, low disease activity = score≤3.2). A negative value in change from BL indicates an improvement. Mixed Model Repeated Measures was used for statistical analysis, which used the change from BL of DAS28-CRP as an outcome and treatment, scheduled study visit, BL value of DAS28-CRP, treatment by visit interaction and BL by visit interaction as fixed effects. The model used the unstructured covariance matrix.

Time frame:
BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12
Units on a scalePF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MR
Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12-2.65 (-2.84 to -2.46)-2.35 (-2.54 to -2.15)-2.30 (-2.49 to -2.11)-2.20 (-2.43 to -1.98)-1.82 (-2.04 to -1.60)
Statistical analysis
  • PF-06650833 400mg MR + Tofacitinib 11mg MR vs Tofacitinib 11mg MR · Mixed Model Repeated Measures · p = 0.0158 · Mean difference (final values): -0.35 · 90% CI -0.62 to -0.08
  • PF-06650833 400mg MR + PF-06651600 100mg vs Tofacitinib 11mg MR · Mixed Model Repeated Measures · p = 0.3933 · Mean difference (final values): -0.04 · 90% CI -0.32 to 0.23
SecondaryDAS28-CRP Remission (<2.6) Rates at Week 24

DAS28-CRP is derived using differential weighting given to 4 components: tender joint count, swollen joint count, patient global assessment, and CRP. Remission is defined as DAS28-CRP score \<2.6. Remission rate = the number of responders (who had remission) / (number of responders + non-responders + non-responder assigned by non-responder imputation \[NRI\] after removal of missingness due to COVID-19 and missing components at a given visit)

Time frame:
Week 24
Reported as:
Number · Percentage of participants
DAS28-CRP Remission (<2.6) Rates at Week 24
Percentage of participantsPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MR
DAS28-CRP Remission (<2.6) Rates at Week 2440.8 (32.6 to 48.7)31.3 (24.1 to 39.8)24.0 (17.1 to 31.8)22.4 (14.8 to 31.3)11.8 (6.7 to 19.3)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs

An adverse event (AE) was any untoward medical occurrence in a patient or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; or other serious situations such as important medical events. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.

Time frame:
From first dose of study intervention (Day 1) to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs
ParticipantsTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mg
All-causality TEAEs6042385155
Treatment-related TEAEs1517132025
All-causality TESAEs33301
Treatment-related TESAEs00000
Discontinuation from study due to all-causality TEAEs20011
Discontinuation from study due to treatment-related TEAEs10010
Study drug withdrawal due to all-causality TEAEs but continued study06646
Study drug withdrawal due to treatment-related TEAEs but continued study04434
SecondaryNumber of Participants With Clinical Laboratory Abnormalities (Hematology and Chemistry, Without Regard to Baseline Abnormality)

Clinical laboratory abnormality was determined at the investigator's discretion.

Time frame:
From BL to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities (Hematology and Chemistry, Without Regard to Baseline Abnormality)
ParticipantsTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mg
Hematology: Hemoglobin (gram per deciliter [g/dL]) <0.8x lower limit of normal (LLN)22022
Erythrocytes (10^6/millimeter^3 [10^6/mm^3]) <0.8x LLN02000
Erythrocyte (Ery.) Mean Corpuscular Volume (micrometer^3 [um^3]) <0.9x LLN32020
Ery. Mean Corpuscular Volume (um^3) >1.1x upper limit of normal (ULN)43434
Ery. Mean Corpuscular Hemoglobin (picogram/cell [pg/cell]) <0.9x LLN85374
Ery. Mean Corpuscular Hemoglobin (HGB) Concentration (g/dL) <0.9x LLN8612104
Platelets (10^3/mm^3) >1.75xULN00010
Reticulocytes/Erythrocytes (%) >1.5x ULN21211
Leukocytes (10^3/mm^3) <0.6x LLN01001
Leukocytes (10^3/mm^3) >1.5x ULN22113
Lymphocytes (10^3/mm^3) <0.8x LLN7163613
Lymphocytes (10^3/mm^3) >1.2x ULN32112
Lymphocytes/Leukocytes (%) <0.8x LLN6119610
Lymphocytes/Leukocytes (%) >1.2x ULN11153
Neutrophils (10^3/mm^3) <0.8x LLN22354
Neutrophils (10^3/mm^3) >1.2x ULN11168514
Neutrophils/Leukocytes (%) <0.8x LLN10021
Neutrophils/Leukocytes (%) >1.2x ULN59637
Basophils (10^3/mm^3) >1.2x ULN00110
Eosinophils (10^3/mm^3) >1.2x ULN00310
Eosinophils/Leukocytes (%) >1.2x ULN10541
Monocytes (10^3/mm^3) >1.2x ULN21102
Monocytes/Leukocytes (%) >1.2x ULN81261117
Activated Partial Thromboplastin Time (second [sec]) >1.1x ULN9991010
Prothrombin Time (sec) >1.1x ULN76629
Erythrocyte Sedimentation Rate (millimeter per hour [mm/hr]) >1.5x ULN7259587163
Clinical Chemistry: Bilirubin (milligram per deciliter [mg/dL]) >1.5x ULN20000
Aspartate Aminotransferase (AST) (unit per liter [U/L]) >3.0x ULN00210
Alanine Aminotransferase (ALT) (U/L) >3.0x ULN01720
Urea Nitrogen (mg/dL) >1.3x ULN41542
Creatinine (mg/dL) >1.3x ULN00010
Urate (mg/dL) >1.2x ULN32241
Cholesterol (mg/dL) >1.3x ULN2213102420
High-Density Lipoprotein (HDL) Cholesterol (mg/dL) <0.8x LLN13101
Low-Density Lipoprotein (LDL) Cholesterol (mg/dL) >1.2x ULN95158
Sodium (milliequivalent per liter [mEq/L]) <0.95x LLN01000
Potassium (mEq/L) <0.9x LLN01201
Potassium (mEq/L) >1.1x ULN23011
Chloride (mEq/L) <0.9x LLN01000
Calcium (mg/dL) <0.9x LLN00001
Bicarbonate (mEq/L) <0.9x LLN42032
Creatine Kinase (U/L) >2.0x ULN471109
Troponin I (nanogram per milliliter [ng/mL]) >1.0x ULN23244
Glucose -FASTING (mg/dL) >1.5x ULN3510102
Triglycerides -FASTING (mg/dL) >1.3x ULN97475
Apolipoprotein A1 (mg/dL) >1.5x ULN01000
Apolipoprotein B (mg/dL) >1.5x ULN01000
SecondaryNumber of Participants With Change From Baseline in Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria

Abnormality in change from BL in vital signs included: sitting/semi-supine diastolic blood pressure (BP) increase and decrease from BL of \>=20mmHg, systolic BP increase and decrease from BL of \>=30mmHg

Time frame:
From BL to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria
ParticipantsTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mg
Diastolic BP increase >=20mmHg12363
Diastolic BP decrease >=20mmHg00000
Systolic BP increase >=30mmHg13423
Systolic BP decrease >=30mmHg00000
SecondaryNumber of Participants With Adverse Events of Special Interest

These AEs included severe and opportunistic infection AEs; herpes virus infection AEs; clinically significant categorical increases in hepatic enzymes AST, and ALT and total bilirubin, and potential cases meeting Hy's Law criteria for increased risk of drug induced liver injury (DILI); major adverse cardiovascular events, including pulmonary embolism and deep vein thrombosis, cerebrovascular accident; AEs for decreased renal function, acute kidney injury, clinically significant increases in serum creatinine (Scr) and decreases in estimated glomerular filtration rate (eGFR). Only participants with AEs mentioned above were reported in the table below.

Time frame:
From first dose of study intervention (Day 1) to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest
ParticipantsTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mg
Herpes Zoster11020
Oral Herpes10012
ALT Increased00320
AST Increased00220
Hyperbilirubinaemia10000
Transaminases Increased00100
Hepatic Enzyme Increased00100
Liver Injury00100
SecondaryChange From Baseline in DAS28-CRP at Week 24

DAS28 is a measure based on assessment of 28 joints for tenderness and swelling (tender and swollen joint counts). DAS28-CRP is derived using differential weighting given to 4 components: tender joint count (range: 0-28), swollen joint count (range: 0-28), patient global assessment (recorded on a visual analog scale \[VAS\] scale of 0-100 mm), and CRP (milligram per liter). DAS28-CRP score ranges from 0 to 9.4. The lower the DAS28-CRP score is, the better the participant has response (remission = score\<2.6, low disease activity = score≤3.2). A negative value in change from BL indicates an improvement.

Time frame:
BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in DAS28-CRP at Week 24
Units on a scalePF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MR
Change From Baseline in DAS28-CRP at Week 24-3.05 (-3.26 to -2.85)-2.87 (-3.08 to -2.65)-2.66 (-2.88 to -2.45)-2.53 (-2.78 to -2.28)-2.26 (-2.51 to -2.00)
SecondaryAmerican College of Rheumatology (ACR)20, ACR 50, ACR 70, and ACR 90 Responder Rates at Week 12 and Week 24

The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR20) is calculated as a \>=20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and CRP. Similarly, ACR50, ACR70, and ACR 90 were calculated with the respective percent improvement. Responder rate = number of responders (who had ACR20/50/70/90 response)/(number of responders + non-responders + non-responder assigned by non-responder imputation \[NRI\] after removal of missingness due to COVID-19 and missing components at a given visit)

Time frame:
BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12, Week 24
Reported as:
Number · Percentage of participants
American College of Rheumatology (ACR)20, ACR 50, ACR 70, and ACR 90 Responder Rates at Week 12 and Week 24
Percentage of participantsPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MR
ACR20 (Week 12)86.41 (79.94 to 91.59)79.21 (71.99 to 85.62)83.17 (75.94 to 88.98)72.73 (63.80 to 80.94)75.00 (66.26 to 82.24)
ACR50 (Week 12)62.75 (54.69 to 70.75)54.46 (45.79 to 62.57)46.53 (38.04 to 55.19)44.16 (34.59 to 54.16)38.16 (29.16 to 47.81)
ACR70 (Week 12)21.36 (15.35 to 28.95)25.74 (19.17 to 33.29)23.76 (16.96 to 31.42)18.18 (11.34 to 26.08)10.53 (5.39 to 18.17)
ACR90 (Week 12)2.91 (1.07 to 6.86)3.96 (1.74 to 8.58)0.99 (0.10 to 4.12)1.30 (0.14 to 5.32)1.32 (0.14 to 5.39)
ACR20 (Week 24)75.73 (68.31 to 82.41)70.00 (61.87 to 77.31)75.25 (67.64 to 82.11)67.53 (57.99 to 76.32)55.26 (45.20 to 65.01)
ACR50 (Week 24)65.05 (57.08 to 72.34)65.00 (56.68 to 72.92)65.35 (57.14 to 73.21)54.55 (44.56 to 63.80)43.42 (33.74 to 53.50)
ACR70 (Week 24)45.63 (37.25 to 54.20)44.00 (35.61 to 52.72)44.55 (36.60 to 53.22)31.17 (22.51 to 40.74)27.63 (19.32 to 36.52)
ACR90 (Week 24)12.62 (8.05 to 19.19)18.00 (12.27 to 25.23)9.90 (5.58 to 16.09)5.19 (2.28 to 11.34)1.32 (0.14 to 5.39)
SecondaryChange From Baseline in the Tender/Painful and Swollen Joint Count at Week 12 and Week 24

The endpoint included Tender/Painful Joint Count 68 (TJC68) and 28 (TJC28). TJC68 was assessed by a blinded joint assessor to determine the number of joints that were considered tender or painful in upper body and upper/lower extremity. The response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). The 28-joints set is the subset of 68 joints set including the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. TJC28 was calculated by Pfizer from TJC68. Higher scores indicate higher level of disability.

Time frame:
BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12, Week 24
Reported as:
Least squares mean · Joints
Change From Baseline in the Tender/Painful and Swollen Joint Count at Week 12 and Week 24
JointsPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MR
TJC28 (Week 12)-9.87 (-10.65 to -9.09)-9.78 (-10.58 to -8.98)-9.84 (-10.63 to -9.05)-9.83 (-10.76 to -8.91)-8.82 (-9.73 to -7.92)
TJC68 (Week 12)-14.96 (-16.09 to -13.83)-15.66 (-16.81 to -14.50)-15.32 (-16.47 to -14.18)-14.80 (-16.13 to -13.46)-13.76 (-15.07 to -12.46)
SJC28 (Week 12)-8.61 (-9.16 to -8.06)-8.16 (-8.73 to -7.60)-7.86 (-8.41 to -7.30)-8.30 (-8.95 to -7.65)-7.80 (-8.44 to -7.15)
SJC66 (Week 12)-11.29 (-11.99 to -10.59)-10.90 (-11.62 to -10.19)-10.34 (-11.05 to -9.63)-10.75 (-11.58 to -9.92)-10.18 (-11.00 to -9.37)
TJC28 (Week 24)-11.33 (-12.06 to -10.61)-11.44 (-12.20 to -10.68)-10.60 (-11.34 to -9.86)-10.47 (-11.34 to -9.59)-10.31 (-11.20 to -9.42)
TJC68 (Week 24)-16.68 (-17.78 to -15.57)-17.68 (-18.82 to -16.53)-16.76 (-17.88 to -15.64)-16.69 (-18.02 to -15.36)-15.79 (-17.13 to -14.46)
SJC28 (Week 24)-8.83 (-9.34 to -8.31)-9.44 (-9.98 to -8.90)-8.76 (-9.29 to -8.24)-8.71 (-9.33 to -8.08)-8.28 (-8.92 to -7.65)
SJC66 (Week 24)-11.41 (-12.02 to -10.80)-12.38 (-13.03 to -11.74)-11.59 (-12.21 to -10.97)-11.45 (-12.19 to -10.71)-11.10 (-11.86 to -10.34)
SecondaryChange From Baseline in the Physician's Global Assessment (PhGA) of Arthritis at Week 12 and Week 24

PhGA of Arthritis is an evaluation done by investigator based on the participant's disease signs, functional capacity and physical examination, and should be independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS. Physician's Global Assessment score ranges from 0 to 100. Higher scores indicate higher level of disability. A negative value in change from BL indicates an improvement.

Time frame:
BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12, Week 24
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Physician's Global Assessment (PhGA) of Arthritis at Week 12 and Week 24
Units on a scalePF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MR
PhGA of Arthritis (Week 12)-43.50 (-46.32 to -40.69)-41.20 (-44.06 to -38.34)-40.86 (-43.72 to -38.00)-38.62 (-41.95 to -35.28)-31.56 (-34.82 to -28.30)
PhGA of Arthritis (Week 24)-47.50 (-50.13 to -44.87)-48.21 (-50.95 to -45.47)-47.31 (-49.98 to -44.63)-43.42 (-46.60 to -40.25)-39.27 (-42.49 to -36.05)

Adverse events

Collected over From first dose of study intervention (Day 1) to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 11mg MR1/102 (1%)3/102 (2.9%)24/102 (23.5%)
PF-06651600 100mg0/77 (0%)3/77 (3.9%)18/77 (23.4%)
PF-06650833 400mg MR0/77 (0%)3/77 (3.9%)11/77 (14.3%)
PF-06650833 400mg MR + Tofacitinib 11mg MR0/103 (0%)0/103 (0%)19/103 (18.4%)
PF-06650833 400mg MR + PF-06651600 100mg0/101 (0%)1/101 (1%)26/101 (25.7%)
Most frequent serious events
Most frequent serious events
EventTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mg
Femur fractureInjury, poisoning and procedural complications0/1021/770/770/1030/101
Diabetic ketoacidosisMetabolism and nutrition disorders0/1021/770/770/1030/101
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/1020/771/770/1030/101
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1021/770/770/1030/101
Renal colicRenal and urinary disorders0/1020/771/770/1030/101
Endometrial hyperplasiaReproductive system and breast disorders0/1020/771/770/1030/101
Uterine polypReproductive system and breast disorders0/1020/771/770/1030/101
COVID-19 pneumoniaInfections and infestations0/1020/770/770/1031/101
Coronavirus infectionInfections and infestations1/1020/770/770/1030/101
Skin squamous cell carcinoma recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1020/770/770/1030/101
Most frequent other events
Most frequent other events
EventTofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mg
SARS-CoV-2 test positiveInvestigations7/1021/772/774/1038/101
HeadacheNervous system disorders4/1024/772/773/1037/101
Urinary tract infectionInfections and infestations5/1021/771/777/1033/101
NauseaGastrointestinal disorders4/1025/772/771/1033/101
ArthralgiaMusculoskeletal and connective tissue disorders3/1025/771/772/1032/101
NasopharyngitisInfections and infestations3/1022/771/773/1036/101
Rheumatoid arthritisMusculoskeletal and connective tissue disorders3/1024/774/771/1031/101

Baseline characteristics

Baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.

Age, Continuous
Age, Continuous(Years)Tofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTotal
Mean51.2 ± 10.6352.8 ± 10.9053.6 ± 9.8754.0 ± 10.4153.0 ± 10.4052.9 ± 10.46
Age, Customized
Age, Customized(Participants)Tofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTotal
18-44251711192193
45-646849567166310
>=6591110131457
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTotal
Female8262617873356
Male2015162528104
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tofacitinib 11mg MRPF-06651600 100mgPF-06650833 400mg MRPF-06650833 400mg MR + Tofacitinib 11mg MRPF-06650833 400mg MR + PF-06651600 100mgTotal
White1017677102101457
Asian100001
Native Hawaiian or Other Pacific Islander000101
Multiracial010001
08

Study locations

144 sites
  • ,,UMHAT - Georgi Stranski" EAD
    Pleven, 5800, Bulgaria
  • Medical Diagnostic Laboratory Rusev EOOD
    Plovdiv, 4000, Bulgaria
  • MHAT Plovdiv AD
    Plovdiv, 4000, Bulgaria
  • DCC Sveti Georgi EOOD
    Plovdiv, 4002, Bulgaria
  • Independent Medical Diagnostic Laboratory Mediscan EOOD
    Plovdiv, Bulgaria
  • "Medical Center-Teodora" EOOD
    Ruse, 7002, Bulgaria
  • UMHAT "Kanev" AD
    Ruse, 7002, Bulgaria
  • Medical Center "Spectar" OOD
    Sofia, 1113, Bulgaria
  • MHAT "Lyulin" EAD
    Sofia, 1336, Bulgaria
  • "DCC 17 - Sofia" EOOD
    Sofia, 1505, Bulgaria
  • Medical Center "N.I. Pirogov" EOOD
    Sofia, 1612, Bulgaria
  • UMHAT "Sveti Ivan Rilski" EAD
    Sofia, 1612, Bulgaria
  • Manitoba Clinic
    Winnipeg, Manitoba R3A 1M3, Canada
  • Centre de Rhumatologie de l'Est du Quebec (CREQ)
    Rimouski, Quebec G5L 8W1, Canada
  • Centro Radiologico San Vicente de Paul
    Santiago, Region Metropolitana 7500509, Chile
  • CTR Estudios
    Santiago, Region Metropolitana 7500571, Chile
  • Enroll SpA
    Santiago, Region Metropolitana 7500587, Chile
  • Centro Radiologico Plaza Baquedano
    Santiago, Region Metropolitana 7500906, Chile
  • IMARED
    Santiago, Region Metropolitana 7501070, Chile
  • Centro de Estudios Reumatologicos (CER)
    Santiago, Region Metropolitana 7501126, Chile
  • CCR Czech a.s.
    Pardubice, Vychodocesky KRAJ 53002, Czechia
  • REVMACLINIC s.r.o.
    Brno, 61141, Czechia
  • Revmacentrum MUDr. Mostera, s.r.o.
    Brno, 615 00, Czechia
  • HV Medical s.r.o., ORL ambulance pro deti a dospele
    Brno, 635 00, Czechia
  • MRI Lekarsky servis s.r.o.
    Havirov, 736 01, Czechia
  • Poliklinika AMO - Audiologie
    Ostrava - Kuncice, 70702, Czechia
  • CCR Ostrava, s.r.o.
    Ostrava, 702 00, Czechia
  • Vesalion s.r.o.
    Ostrava, 702 00, Czechia
  • Mestka nemocnice Ostrava
    Ostrava, 728 80, Czechia
  • ORL - sluchadla s.r.o.
    Pardubice, 530 02, Czechia
  • Poliklinika Vektor
    Pardubice, 530 02, Czechia
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • Thomayerova nemocnice
    Praha 4, 140 59, Czechia
  • ORL ambulance
    Uherske Hradiste, 686 01, Czechia
  • Uherskohradistska nemocnice, a.s.
    Uherske Hradiste, 686 68, Czechia
  • Medical Plus s.r.o.
    Uherske Hradiste, 68601, Czechia
  • JSC "Evex Hospitals"
    Tbilisi, 0159, Georgia
  • LTD "Cardioclinic - Digomi Medical Center"
    Tbilisi, 0159, Georgia
  • LTD "Institute of Clinical Cardiology"
    Tbilisi, 0159, Georgia
  • LTD "MediClub Georgia"
    Tbilisi, 0160, Georgia
  • LTD "Multi-Profile Clinic Consilium Medulla"
    Tbilisi, 0186, Georgia
  • Trial Pharma Kft.
    Bekescsaba, 5600, Hungary
  • Vasutegeszsegugyi Nonprofit Kozhasznu Tarsasag
    Bekescsaba, 5600, Hungary
  • Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz
    Budapest, 1023, Hungary
  • Mammut Egeszsegkozpont, Ful-orr- gegeszet
    Budapest, 1024, Hungary
  • Betegapolo Irgalmasrend Budai Irgalmasrendi Korhaz
    Budapest, 1027, Hungary
  • Budai Irgalmasrendi Korhaz
    Budapest, 1027, Hungary
  • Revita Reumatologiai Rendelo
    Budapest, 1027, Hungary
  • Qualiclinic Kft.
    Budapest, 1036, Hungary
  • Affidea Magyarorszag Kft.
    Budapest, 1054, Hungary
  • Affidea Magyarország Kft. Bank Center Központ
    Budapest, 1054, Hungary
  • Magyar Honvédség Egészségügyi Központ
    Budapest, 1062, Hungary
  • Affidea Magyarorszag Kft. Vaci Greens Egeszsegkozpont
    Budapest, 1138, Hungary
  • Mediszintech Audiologia Kft.
    Budapest, 1148, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, 4032, Hungary
  • Sanitas Diagnosztikai es Rehabilitacios Kozpont
    Gyula, 5700, Hungary
  • Pest Megyei Flór Ferenc Kórház Fül- Orr- Gégészet és Gyermek Fül-Orr-Gégészet
    Kistarcsa, 2143, Hungary
  • Pest Megyei Flór Ferenc Kórház Reumatológiai es Fizioterápiás Osztály
    Kistarcsa, 2143, Hungary
  • Huniko Kereskedelmi és Egészségügyi Szolgáltató Kft.
    Miskolc, 3530, Hungary
  • Szegedi Tudomanyegyetem Reumatologiai Klinika
    Szeged, 6725, Hungary
  • Szegedi Tudomanyegyetem
    Szeged, 6725, Hungary
  • Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 6725, Hungary
  • Csolnoky Ferenc Korhaz, Ful- Orr- Gegeszeti Osztaly
    Veszprem, 8200, Hungary
  • VITAL MEDICAL CENTER (VITÁL-MEDICINA Kft.)
    Veszprém, 8200, Hungary
  • Podlaskie Centrum Sluchu i Mowy Sluchmed
    Bialystok, 15-222, Poland
  • Nzoz Zdrowie Osteo-Medic
    Bialystok, 15-351, Poland
  • Lar-Med
    Bialystok, 15-369, Poland
  • NZOZ Kendron
    Bialystok, 15-402, Poland
  • Tomma Diagnostyka obrazowa
    Bialystok, 15-471, Poland
  • ClinicMed Daniluk, Nowak Sp. J.
    Bialystok, 15-879, Poland
  • Nzoz McD Voxel
    Bydgoszcz, 85-015, Poland
  • Klinika Foniatrii i Audiologii, Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Klinika Reumatologii i Ukladowych Chorob Tkanki Lacznej
    Bydgoszcz, 85-168, Poland
  • Centrum Medyczne Pratia Gdynia
    Gdynia, 81-338, Poland
  • Portowy Zaklad Opieki Zdrowotnej Sp. z o.o.
    Gdynia, 81-338, Poland
  • Centrum Medyczne Enel-Med., Oddzial Alfa Plaza - Gdynia
    Gdynia, 81-366, Poland
  • MCBK
    Grodzisk Mazowiecki, 05-825, Poland
  • Samodzielny Publiczny Specjalistyczny Szpital Zachodni im. sw. Jana Pawla II
    Grodzisk Mazowiecki, 05-825, Poland
  • Malopolskie Badania Kliniczne
    Krakow, 30-002, Poland
  • LUX MED.
    Krakow, 30-004, Poland
  • Centrum Badan Klinicznych JCI
    Krakow, 30-348, Poland
  • Centrum medyczne PLEJADY
    Krakow, 30-363, Poland
  • LUXMED
    Krakow, 30-421, Poland
  • Pratia MCM Krakow
    Krakow, 30-510, Poland
  • Centrum Medycyny Profilaktycznej Sp. z o. o.
    Krakow, 31-513, Poland
  • Centrum Medyczne iMed24
    Krakow, 31-864, Poland
  • FONMED
    Nowa Sol, 67-100, Poland
  • Twoja Przychodnia - Centrum Medyczne Nowa Sol
    Nowa Sol, 67-100, Poland
  • LIVMED Sp. z.o.o.
    Nowy Tomysl, 64-300, Poland
  • Ai Centrum Medyczne
    Poznan, 61-113, Poland
  • Tomma Diagnostyka Obrazowa S.A.
    Poznan, 61-361, Poland
  • GEERS Dobry Sluch
    Poznan, 61-397, Poland
  • Prywatna Praktyka Lekarska Prof. dr hab. med. Pawel Hrycaj
    Poznan, 61-397, Poland
  • Pracownia Rezonansu Magnetycznego i RTG
    Poznan, 61-545, Poland
  • Centrum Mowy i Sluchu Medincus
    Warszawa, 00-024, Poland
  • Rex Medica Sport
    Warszawa, 00-838, Poland
  • Medycyna Kliniczna
    Warszawa, 00-874, Poland
  • Tomma Diagnostyka Obrazowa
    Warszawa, 01-201, Poland
  • "MTZ CLINICAL RESEARCH" Spolka z ograniczona odpowiedzialnoscia
    Warszawa, 02-106, Poland

Showing the first 100 of 144 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Feb 2022, 18 months.

Results were first posted in Apr 2023, 1 year 2 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 18 months is close to that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2020
First posted
Jun 4, 2020
StartActual
Jul 29, 2020
Primary completionActual
Feb 7, 2022
CompletionActual
Feb 7, 2022
Results first posted
Apr 7, 2023
Last update
Apr 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04413617
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Jul 29, 2020
Primary completion
Feb 7, 2022
Completion
Feb 7, 2022
Results posted
Apr 7, 2023
Last update
Apr 7, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zimlovisertib · PF-06651600 · Tofacitinib

Start the discussion